Junshi Biosciences Announces the Phase 3 Study of JS005 (IL-17A) for the Treatment of Moderate to Severe Plaque Psoriasis Met Primary Endpoints
SHANGHAI, Sept. 07, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd…
SciSparc: AutoMaxs Shareholders Approve Merger with SciSparc
TEL AVIV, Israel, Aug. 28, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq:…
Three years to go: LA28 competition schedule revealed as PlayLA programme surpasses one million registrations
15 July 2025 - With three years to go until the Opening Ceremony…
